(Q43164702)

15 November 2017

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck (English)

1 reference

15 November 2017

Naomi Kiyota

16

0 references

Lisa Licitra

object named as

Lisa Licitra

6

0 references

Everett E Vokes

9

object named as

Everett E Vokes

1 reference

15 November 2017

George R Blumenschein

2

object named as

George Blumenschein

1 reference

15 November 2017

23

Maura L Gillison

1 reference

15 November 2017

1

Robert L Ferris

1 reference

15 November 2017

Jerome Fayette

3

1 reference

15 November 2017

Joel Guigay

4

1 reference

15 November 2017

A Dimitrios Colevas

5

1 reference

15 November 2017

Kevin Harrington

7

1 reference

15 November 2017

Stefan Kasper

8

1 reference

15 November 2017

Caroline Even

10

1 reference

15 November 2017

Francis Worden

11

1 reference

15 November 2017

Nabil F Saba

12

1 reference

15 November 2017

Lara C Iglesias Docampo

13

1 reference

15 November 2017

Robert Haddad

14

1 reference

15 November 2017

Tamara Rordorf

15

1 reference

15 November 2017

Makoto Tahara

17

1 reference

15 November 2017

Manish Monga

18

1 reference

15 November 2017

Mark Lynch

19

1 reference

15 November 2017

William J Geese

20

1 reference

15 November 2017

Justin Kopit

21

1 reference

15 November 2017

James W Shaw

22

1 reference

15 November 2017

language of work or name

English

0 references

publication date

8 October 2016

1 reference

The New England Journal of Medicine

15 November 2017

1 reference

15 November 2017

375

1 reference

15 November 2017

1856-1867

1 reference

15 November 2017

19

1 reference

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

15 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

Immunology and Immunotherapy of Head and Neck Cancer

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

Immune checkpoint blockade: a common denominator approach to cancer therapy

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

Interpreting the significance of changes in health-related quality-of-life scores.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

A Multiple Testing Procedure for Clinical Trials

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5564292

1 December 2018

Identifiers

DOI

10.1056/NEJMOA1602252

1 reference

15 November 2017

1 reference

15 November 2017

1 reference